PTN
$23.23
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
Recent News
Palatin Technologies, Inc. Q2 2026 Earnings Call Summary
Moby summary of Palatin Technologies, Inc.'s Q2 2026 earnings call
Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
Despite a significant net loss, Palatin Technologies Inc (PTN) strengthens its financial position with a successful public offering and advances in its obesity treatment pipeline.
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
Palatin Technologies Inc (PTNT) reports significant progress in clinical trials and cost reductions, despite facing financial hurdles and stock delisting issues.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 353% surge in interest Protagenic Therapeutics (PTIX), 345% surge in interest Hepion Pharmaceuticals (HEPA), 310% surge in interest Rigel Pharmaceuticals (RIGL), 290% surge in interest Bolt Biotherapeutics (BOLT), 274% surge in interest Palatin Technologies (PTN), 274% surge in interest Krystal Biotech (KRYS), 240% surge in
Top Premarket Gainers
Third Harmonic Bio (THRD) shares rose 40% in recent Monday premarket activity, after saying its boar